2020
Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation
HORSKÁ, Kateřina, Hana KOTOLOVÁ, Michal KARPÍŠEK, Zuzana BABINSKÁ, Tomáš HAMMER et. al.Základní údaje
Originální název
Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation
Název česky
Metabolický profil tří antipsychotik v depotních formulacích u potkanů v methylazoxymethanolovém modelu schizofrenie
Autoři
HORSKÁ, Kateřina (203 Česká republika, domácí), Hana KOTOLOVÁ (203 Česká republika, domácí), Michal KARPÍŠEK (203 Česká republika, domácí), Zuzana BABINSKÁ (703 Slovensko, domácí), Tomáš HAMMER (203 Česká republika, domácí), Jiří PROCHÁZKA (203 Česká republika, domácí), Tibor ŠTARK (703 Slovensko, domácí), Vincenzo MICALE (380 Itálie) a Jana RUDÁ (203 Česká republika, garant, domácí)
Vydání
Toxicology and applied pharmacology, San Diego, Elsevier, 2020, 0041-008X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30104 Pharmacology and pharmacy
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 4.219
Kód RIV
RIV/00216224:14110/20:00116401
Organizační jednotka
Lékařská fakulta
UT WoS
000580522200009
Klíčová slova anglicky
Adipokine; Antipsychotic; Lipid Profile; Methylazoxymethanol; Rats
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 12. 5. 2021 13:50, Mgr. Tereza Miškechová
Anotace
V originále
Mortality in psychiatric patients with severe mental illnesses reaches a 2-3 times higher mortality rate compared to the general population, primarily due to somatic comorbidities. A high prevalence of cardiovascular morbidity can be attributed to the adverse metabolic effects of atypical antipsychotics (atypical APs), but also to metabolic dysregulation present in drug-naive patients. The metabolic aspects of neurodevelopmental schizophrenia-like models are understudied. This study evaluated the metabolic phenotype of a methylazoxymethanol (MAM) schizophrenia-like model together with the metabolic effects of three APs [olanzapine (OLA), risperidone (RIS) and haloperidol (HAL)] administered via long-acting formulations for 8 weeks in female rats. Body weight, feed efficiency, serum lipid profile, gastrointestinal and adipose tissue-derived hormones (leptin, ghrelin, glucagon and glucagon-like peptide 1) were determined. The lipid profile was assessed in APs-naive MAM and control cohorts of both sexes. Body weight was not altered by the MAM model, though cumulative food intake and feed efficiency was lowered in the MAM compared to CTR animals. The effect of the APs was also present; body weight gain was increased by OLA and RIS, while OLA induced lower weight gain in the MAM rats. Further, the MAM model showed lower abdominal adiposity, while OLA increased it. Serum lipid profile revealed MAM model-induced alterations in both sexes; total, HDL and LDL cholesterol levels were increased. The MAM model did not exert significant alterations in hormonal parameters except for elevation in leptin level. The results support intrinsic metabolic dysregulation in the MAM model in both sexes, but the MAM model did not manifest higher sensitivity to metabolic effects induced by antipsychotic treatment.
Návaznosti
| MUNI/A/1292/2019, interní kód MU |
| ||
| ROZV/28/LF19/2020, interní kód MU |
| ||
| 3SGA5789, interní kód MU |
|